CHRS
Coherus BioSciences Inc.
$1.59
-$0.02(-1.24%)
50
Overall
--
Value
50
Tech
--
Quality
Market Cap
$187.13M
Volume
984.50K
52W Range
$0.66 - $2.43
Target Price
$4.51
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $30.0M | $190.1M | $1.6M | -- | $356.1M | $475.8M | $326.6M | $211.0M | $257.2M | $267.0M | ||
| Total Revenue | $30.0M | $190.1M | $1.6M | -- | $356.1M | $475.8M | $326.6M | $211.0M | $257.2M | $267.0M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | -- | -- | $17.1M | $37.7M | $57.6M | $70.1M | $159.0M | $117.6M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $30.0M | $190.1M | $1.6M | -- | $339.0M | $438.2M | $269.0M | $141.0M | $98.3M | $149.4M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-249.1M | $-306.0M | $-233.7M | $-204.4M | $231.2M | $281.8M | $532.8M | $397.8M | $301.5M | $261.1M | ||
| Research & Development | $213.1M | $254.4M | $162.4M | $110.2M | $94.2M | $142.8M | $363.1M | $199.4M | $109.4M | $93.3M | ||
| Research Expense | $213.1M | $254.4M | $162.4M | $110.2M | $94.2M | $142.8M | $363.1M | $199.4M | $109.4M | $93.3M | ||
| Selling, General & Administrative | $36.0M | $51.6M | $71.3M | $94.2M | $137.0M | $139.1M | $169.7M | $198.5M | $192.0M | $167.7M | ||
| Selling & Marketing Expenses | $-559.0K | $-178.0K | $71.3M | $94.2M | $4.5M | $3.8M | $8.7M | $10.5M | $10.9M | $10.9M | ||
| General & Administrative Expenses | $36.0M | $51.6M | $-2.3M | $-2.2M | $137.0M | $139.1M | $169.7M | $198.5M | $192.0M | $167.7M | ||
| Salaries & Wages | -- | $-27.4M | $-33.4M | $-34.8M | $1.7M | $1.5M | $1.0M | $50.7M | $43.1M | $27.8M | ||
| Depreciation & Amortization | $-1.9M | $-3.0M | $-3.4M | $-3.2M | $3.3M | $2.9M | $3.5M | $3.6M | $3.2M | $1.8M | ||
| Depreciation & Amortization | $-1.9M | $-3.0M | $-3.4M | $-3.2M | $3.3M | $2.9M | $3.5M | $3.6M | $3.2M | $1.8M | ||
| Amortization | $38.0K | $-1.0M | $-1.4M | $-1.5M | $5.0M | $6.1M | $7.8M | $7.4M | $3.4M | $7.6M | ||
| Other Operating Expenses | $-249.1M | $-306.0M | $-233.7M | $-204.4M | $-1.2M | $-1.7M | $-2.0M | $-1.4M | $-865.0K | $-1.6M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-219.1M | $-115.9M | $-233.7M | $-204.4M | $107.8M | $156.3M | $-263.9M | $-256.9M | $-203.2M | $-111.7M | ||
| EBITDA | $-222.1M | $-115.8M | $-224.1M | $-195.3M | $115.8M | $159.8M | $-260.7M | $-249.2M | $-191.5M | $65.1M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $33.0K | $8.0M | $9.6M | $9.7M | $17.6M | $21.2M | $23.0M | $32.5M | $40.5M | $27.2M | ||
| Intinc | -- | -- | -- | -- | $1.6M | $3.3M | $1.4M | $1.9M | $2.8M | $4.5M | ||
| Net Non-Operating Interest Income/Expense | $-33.0K | $-8.0M | $-9.6M | $-9.7M | $-17.6M | $-21.2M | $-23.0M | $-32.5M | $-40.5M | $-27.2M | ||
| Other Income/Expense | $4.8M | $3.9M | $-5.0M | $-4.7M | $-2.6M | $-554.0K | $283.0K | $-2.4M | $-5.5M | $-167.3M | ||
| Other Special Charges | $-4.8M | $-3.9M | $5.0M | $4.7M | $2.6M | $554.0K | $-283.0K | $-2.4M | $5.5M | $-9.3M | ||
| SPECIAL ITEMS | ||||||||||||
| Other Impairment Of Capital Assets | -- | -- | $-600.0K | $-3.9M | $100.0K | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-223.9M | $-119.8M | $-228.7M | $-199.7M | $110.4M | $156.9M | $-264.1M | $-259.3M | $-197.7M | $55.7M | ||
| Pre-Tax Income | $-223.9M | $-127.8M | $-238.3M | $-209.4M | $92.8M | $135.7M | $-287.1M | $-291.8M | $-238.3M | $28.5M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | -- | -- | $2.9M | $3.5M | -- | -- | $-380.0K | -- | ||
| NET INCOME | ||||||||||||
| Net Income | $-223.3M | $-127.3M | $-238.2M | $-209.3M | $89.8M | $132.2M | $-287.1M | $-291.8M | $-237.9M | $28.5M | ||
| Net Income (Continuing Operations) | $-223.3M | $-127.3M | $-238.2M | $-209.3M | $89.8M | $132.2M | $-287.1M | $-291.8M | $-237.9M | $28.5M | ||
| Net Income (Discontinued Operations) | $-223.3M | $-127.3M | $-238.2M | $-209.3M | $89.8M | $132.2M | $-287.1M | $-291.8M | $-237.9M | $28.5M | ||
| Net Income (Common Stockholders) | $-223.3M | $-127.3M | $-238.2M | $-209.3M | $89.9M | $132.2M | $-287.1M | $-291.8M | $-237.9M | $28.5M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $-148.4M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-249.1M | $-306.0M | $-233.7M | $-204.4M | $248.3M | $319.5M | $590.4M | $467.9M | $460.4M | $378.6M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $37.1M | $41.9M | $53.1M | $65.0M | $69.7M | $71.4M | $75.4M | $77.6M | $94.2M | $114.6M | ||
| Average Shares Outstanding (Diluted) | $37.1M | $41.9M | $53.2M | $65.0M | $73.2M | $83.5M | $75.4M | $77.6M | $94.2M | $114.8M | ||
| Shares Outstanding | $39.1M | $51.1M | $60.1M | $69.3M | $70.6M | $72.8M | $77.3M | $79.6M | $112.7M | $115.9M | ||
| Basic EPS | -- | $-1.71 | -- | $-3.22 | $1.29 | $1.85 | $-3.81 | $-3.76 | $-2.53 | $0.25 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $1.29 | $1.85 | $-3.81 | $-3.76 | $-2.53 | $0.25 | ||
| Diluted EPS | $-6.01 | $-3.04 | $-4.48 | $-3.22 | $1.23 | $1.62 | $-3.81 | $-3.76 | $-2.53 | $0.25 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $1.23 | $1.62 | $-3.81 | $-3.76 | $-2.53 | $0.25 | ||
| OTHER METRICS | ||||||||||||
| Gain On Sale Of P P E | -- | -- | -- | -- | -- | -- | -- | -- | -- | $176.6M | ||
| Marketing Expense | -- | -- | -- | $-2.8M | $4.5M | $3.8M | $8.7M | $10.5M | $10.9M | $10.9M | ||
| Minority Interests | $678.0K | $451.0K | $116.0K | $70.0K | $105.2M | -- | -- | -- | -- | -- | ||
| Other Gand A | $36.0M | $51.6M | $-2.3M | $-2.2M | $137.0M | $139.1M | $169.7M | $198.5M | $192.0M | $167.7M | ||
| Rent And Landing Fees | $36.0M | $51.6M | $-2.3M | $-2.2M | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | -- | -- | $71.3M | $94.2M | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CHRS | $1.59 | -1.2% | 984.50K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Coherus BioSciences Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW